[开心]_老虎社区_美港股上老虎

KTAN
2021-10-15

[开心]

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

There are good reasons behind analysts' optimism about these stocks.

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":824882848,"tweetId":"824882848","gmtCreate":1634302059646,"gmtModify":1634302308006,"author":{"id":3582677171041730,"authorId":3582677171041730,"authorIdStr":"3582677171041730","name":"KTAN","avatar":"https://static.tigerbbs.com/ce6441dbbb7357a69965327b29de9f2b","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[开心]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[开心]&nbsp;</span></p></body></html>","text":"[开心]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/824882848","repostId":2175112197,"repostType":4,"repost":{"id":"2175112197","pubTimestamp":1634300119,"share":"https://www.laohu8.com/m/news/2175112197?lang=&edition=full","pubTime":"2021-10-15 20:15","market":"us","language":"en","title":"3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More","url":"https://stock-news.laohu8.com/highlight/detail?id=2175112197","media":"Motley Fool","summary":"There are good reasons behind analysts' optimism about these stocks.","content":"<p>You might be surprised by how many of the best-performing stocks don't have great bottom lines. Posting big net losses quarter over quarter doesn't necessarily prevent stocks from delivering tremendous gains.</p>\n<p>Many investors, though, prefer to invest in companies that continually generate solid earnings. It's even better when these companies have attractive near-term prospects.&nbsp;Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ad374758dff4c3cd9a2de22300dc56f1\" tg-width=\"700\" tg-height=\"465\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>1. Bristol Myers Squibb</h2>\n<p>The consensus price target for&nbsp;<b>Bristol Myers Squibb</b> (NYSE:BMY) is 39% above the big drugmaker's current share price. Why are analysts so optimistic about the pharma stock when its shares are down close to 8% year to date? There are two main reasons.</p>\n<p>First, BMS stock is basically dirt cheap right now. Its shares trade at a little over seven times expected earnings. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the <b>S&amp;P 500</b>.</p>\n<p>Second, BMS has several drugs with strong growth potential. These include current blockbusters such as blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy. Newer products, including cancer cell therapies Abecma and Breyanzi, should also emerge as big winners for the company in the near future.</p>\n<p>The biggest yellow flag for BMS is that its top-selling drug Revlimid faces generic competition beginning next year. However, the volumes for generics will be limited at first, thanks to contractual restrictions. This gives the company more time for its newer drugs to gain traction in the marketplace.</p>\n<h2>2. Biogen</h2>\n<p>Earlier this year,&nbsp;<b>Biogen</b> (NASDAQ:BIIB) was handily beating the market, with shares soaring nearly 70%. The biotech stock has since given up much of that impressive gain. However, Wall Street remains bullish about Biogen, with the average analyst's 12-month price target reflecting an upside potential of 41%.</p>\n<p>Biogen certainly faces some challenges. Momentum for its multiple sclerosis franchise continues to wane due to generic competition for Tecfidera. Spinal muscular atrophy drug Spinraza is no longer the tremendous growth driver that it once was.</p>\n<p>The company's hopes now largely depend on Alzheimer's-disease drug Aduhelm. However, it's possible that sales for the drug could be disappointing. Aduhelm is running into pushback from payers and physicians due to concerns that it's not effective. The U.S. Food and Drug Administration (FDA) has also received reports of potentially serious safety issues with the drug.</p>\n<p>No <a href=\"https://laohu8.com/S/AONE.U\">one</a> should count Aduhelm out yet, though. If the Alzheimer's disease drug comes anywhere close to achieving analysts' peak sales estimates, Biogen's share price could rebound significantly.</p>\n<h2>3. Vertex Pharmaceuticals</h2>\n<p>Wall Street's consensus price target for&nbsp;<b>Vertex Pharmaceuticals</b> (NASDAQ:VRTX) is 42% above the current share price for the biotech. There's no doubt that Vertex's cystic fibrosis (CF) drugs are the main factor behind this optimistic outlook.</p>\n<p>No other company is even close to launching a drug that treats the underlying cause of CF. Meanwhile, Vertex already has four approved CF therapies. But the company still hasn't fully capitalized on its monopoly. More than 30,000 of the estimated 83,000 eligible patients for Vertex's drugs aren't on the treatments yet.</p>\n<p>The big biotech also hopes to expand beyond CF. Vertex and its partner <b>CRISPR Therapeutics</b> could be in a position to file for regulatory approvals of gene-editing therapy CTX001 in treating rare blood diseases beta-thalassemia and sickle cell disease in 2023. Vertex's pipeline also includes a couple of phase 2 programs, one targeting rare kidney diseases and the other targeting pain.</p>\n<p>Some might view Vertex's pipeline as relatively light. That could change in the not-too-distant future, though. The company's cash stockpile tops $6.7 billion. Vertex's management has hinted at plans to use its cash to bolster the pipeline through business-development deals.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-15 20:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/15/3-highly-profitable-stocks-wall-street-thinks-will/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You might be surprised by how many of the best-performing stocks don't have great bottom lines. Posting big net losses quarter over quarter doesn't necessarily prevent stocks from delivering ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/15/3-highly-profitable-stocks-wall-street-thinks-will/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司","VRTX":"福泰制药","BMY":"施贵宝"},"source_url":"https://www.fool.com/investing/2021/10/15/3-highly-profitable-stocks-wall-street-thinks-will/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175112197","content_text":"You might be surprised by how many of the best-performing stocks don't have great bottom lines. Posting big net losses quarter over quarter doesn't necessarily prevent stocks from delivering tremendous gains.\nMany investors, though, prefer to invest in companies that continually generate solid earnings. It's even better when these companies have attractive near-term prospects. Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months.\nImage source: Getty Images.\n1. Bristol Myers Squibb\nThe consensus price target for Bristol Myers Squibb (NYSE:BMY) is 39% above the big drugmaker's current share price. Why are analysts so optimistic about the pharma stock when its shares are down close to 8% year to date? There are two main reasons.\nFirst, BMS stock is basically dirt cheap right now. Its shares trade at a little over seven times expected earnings. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.\nSecond, BMS has several drugs with strong growth potential. These include current blockbusters such as blood thinner Eliquis and cancer immunotherapies Opdivo and Yervoy. Newer products, including cancer cell therapies Abecma and Breyanzi, should also emerge as big winners for the company in the near future.\nThe biggest yellow flag for BMS is that its top-selling drug Revlimid faces generic competition beginning next year. However, the volumes for generics will be limited at first, thanks to contractual restrictions. This gives the company more time for its newer drugs to gain traction in the marketplace.\n2. Biogen\nEarlier this year, Biogen (NASDAQ:BIIB) was handily beating the market, with shares soaring nearly 70%. The biotech stock has since given up much of that impressive gain. However, Wall Street remains bullish about Biogen, with the average analyst's 12-month price target reflecting an upside potential of 41%.\nBiogen certainly faces some challenges. Momentum for its multiple sclerosis franchise continues to wane due to generic competition for Tecfidera. Spinal muscular atrophy drug Spinraza is no longer the tremendous growth driver that it once was.\nThe company's hopes now largely depend on Alzheimer's-disease drug Aduhelm. However, it's possible that sales for the drug could be disappointing. Aduhelm is running into pushback from payers and physicians due to concerns that it's not effective. The U.S. Food and Drug Administration (FDA) has also received reports of potentially serious safety issues with the drug.\nNo one should count Aduhelm out yet, though. If the Alzheimer's disease drug comes anywhere close to achieving analysts' peak sales estimates, Biogen's share price could rebound significantly.\n3. Vertex Pharmaceuticals\nWall Street's consensus price target for Vertex Pharmaceuticals (NASDAQ:VRTX) is 42% above the current share price for the biotech. There's no doubt that Vertex's cystic fibrosis (CF) drugs are the main factor behind this optimistic outlook.\nNo other company is even close to launching a drug that treats the underlying cause of CF. Meanwhile, Vertex already has four approved CF therapies. But the company still hasn't fully capitalized on its monopoly. More than 30,000 of the estimated 83,000 eligible patients for Vertex's drugs aren't on the treatments yet.\nThe big biotech also hopes to expand beyond CF. Vertex and its partner CRISPR Therapeutics could be in a position to file for regulatory approvals of gene-editing therapy CTX001 in treating rare blood diseases beta-thalassemia and sickle cell disease in 2023. Vertex's pipeline also includes a couple of phase 2 programs, one targeting rare kidney diseases and the other targeting pain.\nSome might view Vertex's pipeline as relatively light. That could change in the not-too-distant future, though. The company's cash stockpile tops $6.7 billion. Vertex's management has hinted at plans to use its cash to bolster the pipeline through business-development deals.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1109,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

3 Highly Profitable Stocks Wall Street Thinks Will Soar 39% or More

评论（1）

热议股票